Protagonist Therapeutics, Inc. announced that Pivotal Phase 3 VERIFY study of rusfertide in polycythemia vera expected to initiate in first quarter of 2022. Topline results from the Phase 2 IDEAL study of PN-943 in ulcerative colitis expected in second quarter of 2022. Dosing has begun in a 240-patient Phase 2b clinical trial of PN-235 in moderate-to-severe plaque psoriasis, sponsored by Janssen.